Physician

Suresh Kunapareddy, M.D.

According to 2025 Medicare claims, Suresh Kunapareddy, M.D. (NPI: 1285742296) practices medical oncology in the Terre Haute, IN market, with the plurality of this provider's patient population coming from Vigo, IN. This provider's primary affiliated billing organization is UNION ASSOCIATED PHYSICIANS CLINIC, LLC (NPI: 1891028379; TIN: 27-0581401) and primary practice location at 47804-2766. Kunapareddy is affiliated with the IRCCO (ACO ID: A2619), Central Florida ACO (ACO ID: A2801), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Kunapareddy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 722 traditional Medicare patients, billed 2,605 HCPCS/CPT codes, and received $180,983 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,895 prescription claims across 296 beneficiaries totaling $3,579,644 in drug costs, led by Tasigna (Nilotinib Hcl). 2023 DME data shows 68 claims. Open Payments data shows 121 records totaling $3,710. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $444,303 to $180,983. In contrast, Part D prescription costs have risen steadily, from $1,204,871 to $3,579,644. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $23,366 to $868.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,035	16,800	$444,303
2016	1,022	17,870	$448,666
2017	973	16,890	$403,488
2018	913	14,852	$364,980
2019	922	13,484	$325,078
2020	804	10,366	$244,402
2021	1,019	13,037	$382,828
2022	917	3,254	$236,019
2023	823	2,860	$174,295
2024	722	2,605	$180,983

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	253	1,626	$1,204,871
2016	261	1,670	$1,324,884
2017	251	1,496	$1,579,867
2018	247	1,334	$1,590,745
2019	249	1,337	$2,263,342
2020	212	1,082	$1,770,328
2021	284	1,354	$2,195,752
2022	278	1,382	$1,618,131
2023	288	1,587	$2,113,218
2024	296	1,895	$3,579,644

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	46	341	$53,834
2016	54	254	$31,687
2017	12	59	$2,747
2018	N/R	24	$860
2019	N/R	37	$3,166
2020	N/R	37	$3,367
2021	N/R	N/R	N/R
2022	N/R	48	$1,359
2023	N/R	68	$28,715
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	49	49	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	142	274	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	412	1,343	$70
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	75	188	$57
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	394	528	$45

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tasigna	Nilotinib Hcl	18	479	$311,833
Revlimid	Lenalidomide	17	399	$270,268
Verzenio	Abemaciclib	13	364	$204,276
Brukinsa	Zanubrutinib	13	390	$190,563
Bosulif	Bosutinib	12	360	$176,992

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	121	$3,710	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Suresh Kunapareddy, M.D.?

Tedicare shows public-source Medicare data for Suresh Kunapareddy, M.D. (NPI 1285742296), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Suresh Kunapareddy, M.D. have ACO affiliation data?

Suresh Kunapareddy, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), Central Florida ACO (MSSP, ACO ID A2801), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Suresh Kunapareddy, M.D.?

Suresh Kunapareddy, M.D. is linked to UNION ASSOCIATED PHYSICIANS CLINIC, LLC (billing NPI 1891028379) in the available physician profile data.

Does Suresh Kunapareddy, M.D. have Open Payments data?

Suresh Kunapareddy, M.D. has 121 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.